Effect of uridine coadministration on 5′-deoxy-5-fluorouridine disposition in rats

Cancer Chemotherapy and Pharmacology - Tập 22 - Trang 5-10 - 1988
J. Lai-Sim Au1, M. Guillaume Wientjes1, Steven L. Bramer1
1College of Pharmacy, The Ohio State University, Columbus, USA

Tóm tắt

Uridine (UR) inhibits the metabolic activation of 5′-deoxy-5-fluorouridine (dFUR) to 5-fluorouracil (FU) by the intestinal pyrimidine nucleoside phosphorylases and could potentially reduce its intestinal toxicity. This study examined the effect of UR coadministration on the absorption and disposition of an oral dose of dFUR. Rats were given dFUR alone (500 mg kg-1) and dFUR (300 mg kg-1) plus UR (4.5 g kg-1) in a random crossover experiment. Simultaneous injection of a tracer dose of [6-3H]dFUR was used to asses the total body clearance (Cl) of dFUR. The absorption of UR was rapid and variable. The UR dose produced a maximal blood concentration of 80 μg/ml for UR and 100 μg/ml for its metabolite uracil (U). The absorption of dFUR was slower than UR, as indicated by its later time of maximal concentration. UR did not alter the Cl of dFUR, but reduced the absorption rate of dFUR from the gastrointestinal tract and significantly reduced the absolute oral bioavailability of dFUR from 55.2% to 33.4%. The effects of UR coadministration on the dFUR metabolite FU were opposite to those on dFUR; the FU availability was increased sixfold, and the elimination of FU was reduced. Based on the known competition between pyrimidine bases for their saturable metabolic enzymes, the increase in FU availability by UR coadministration was likely due to a competitive inhibition of FU metabolism by U. This study established the complex pharmacokinetic interactions between dFUR and UR and between their metabolites, which may be important in the modulation of dFUR activity by UR.

Tài liệu tham khảo

Abele R, Alberto P, Seematter RJ, Germano F, Heintz R, Bollag W (1982) Phase I clinical study with 5′-deoxy-5-fluorouridine, a new fluoropyrimidine derivative. Cancer Treat Rep 66:1307

Alberto P, Rozencweig M, Clavel M, Siegenthaler P, Cavalli F, Gundersen S, Bruntsch U, Renard J, Pinedo H (1986) Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma. Cancer Chemother Pharmacol 16:78

Armstrong RD, Cadman E (1983) 5′-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. Cancer Res 43:2525

Armstrong RD, Diasio RB (1980) Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res 40:3333

Au JL-S (1985) Effect of age on the disposition and tissue clearances of fluorinated pyrimidines in rats. Pharm Res 2:279

Au JL-S (1987) Disposition and availability of the 5-fluorouracil prodrug 5′-deoxy-5-fluorouridine after oral administration to rats. J Pharm Sci 76:699

Au JL-S, Rustum YM, Mittelman A, Ledesma E, Creaven PJ (1982) Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in the treatment of colorectal adenocarcinoma. Cancer Res 42:2930

Au JL-S, Rustum YM, Minowada J, Srivastava BIS (1983) Differential selectivity of 5-fluorouracil and 5′-deoxy-5-fluororouridine in cultured human B lymphocytes and mouse L1210 leukemia. Biochem Pharmacol 32:541

Au JL-S, Walker JS, Rustum YM (1983) Pharmacokinetic studies of 5-fluorouracil and 5′-deoxy-5-fluorouridine in rats. J Pharmacol Exp Ther 227:174

Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady state volume of distribution. J Pharm Sci 68: 1071

Bowen D, Enigboken MA, Diasio RB (1982) 5′-Deoxy-5-fluorouridine, a model substrate for the study of pyrimidine nucleoside transport. Proc Am Assoc Cancer Res 23:219

Chabner B (1982) Pyrimidine antagonist: In: Chabner BA (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, p 183

Cook AF, Holman MJ, Kramer MJ, Trown PW (1979) Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 22:1330

Covey JM, Straw JA (1983) Nonlinear pharmacokinetics of thymidine, thymine, fluorouracil, and their kinetic interactions in normal dogs. Cancer Res 43:4587

de Bruijn EA, van Oosterom AT, Tjaden UR, Reeuwijk HJEM, Pinedo HM (1985) Pharmacology of 5′-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res 45:5931

Gasser T, Moyer JD, Handschumacher RE (1981) Novel single-pass exchange of circulating uridine in rat liver. Science 213:777

Hartmann HR, Bollag W (1986) Modulation of the effects of fluorinated pyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine. Med Oncol Tumor Pharmacother 3:111

Heinz RC, Guentert TW, Sutter C, Linder-Ciccolunghi SN (1986) Pharmacokinetic profile of doxifluridine (5-dFUR, Furtulon®), A 5-fluorouracil (5-FU) pro-drug. Proc Am Assoc Cancer Res 27:207

Ishituka H, Miwa M, Takemoto K, Kukuoka K, Itoga A, Maruyama HB (1980) Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 71:112

Klubes P, Geffen DB, Sysyk RL (1986) Comparison of the bioavailability of uridine in mice after either oral or parenteral administration. Cancer Chemother Pharmacol 17:236

Kurz H (1980) Principles of drug absorption. In: Forth B, Rummel W (eds) Pharmacology of intestinal absorption. Pergamon, New York, p 245

Levya A, van Groeningen CJ, Kraal I, Gall H, Peters GJ, Lankelma J, Pinedo HM (1984) Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluourouracil toxicity. Cancer Res 44:5928

Loo JCK, Riegelman S (1968) New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 57:918

Monks A, Cysyk RL (1982) Uridine regulation by the isolated rat liver: perfusion with an artifical oxygen carrier. Am J Physiol 242:R465

Rowland M, Tozer TN (1980) Clinical pharmacokinetics, concepts and applications. Lea and Febiger, Philadelphia

Schanker LS (1971) Drug absorption: In: Fundamentals of drug metabolism and drug disposition. LaDu BN, Mandel HG, Way EL (eds) Williams and Wilkins, Baltimore, pp 22

Sommadossi JP, Aubert C, Cano JP, Gouveia J, Ribaud P, Mathe G (1983) Kinetics and metabolism of a new fluoropyrimidine, 5′-deoxy-5-fluorouridine in humans. Cancer Res 43:930

Taguchi T, Kimura K, Saito T (1985) Oral administration of 5′-deoxy-5-fluorouridine (5′-dFUR) in breast cancer. Proc 3rd Eur Conf Clin Oncol Cancer Nurs (Stockholm), p 12

Trave F, Cannobio L, Au JL-S, Rustum YM (1987) Role of route of administration in the therapeutic efficacy of 5′-deoxy-5-fluorouridine in rats. J Natl Cancer Inst 78:527

Van Groeningen C, Peters G, Nadal J, Leyva A, Gall H, Pinedo H (1987) Phase I clinical and pharmacokinetic study of orally administered UR. Proc Am Assoc Cancer Res 28:195

Wientjes MG, Au JL-S (1987) Inhibition of intestinal pyrimidine nucleoside phosphorylases. Pharmaceut Res 4:425

Thông tin
Thông tin xuất bản

Cancer Chemotherapy and Pharmacology

Tập 22

5-10

Thông tin tác giả